Versartis, Inc. (VSAR) Director Purchases $893,961.00 in Stock

Versartis, Inc. (NASDAQ:VSAR) Director Srinivas Akkaraju acquired 419,700 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The stock was bought at an average cost of $2.13 per share, for a total transaction of $893,961.00. Following the completion of the transaction, the director now directly owns 14,955 shares in the company, valued at approximately $31,854.15. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Srinivas Akkaraju also recently made the following trade(s):

  • On Monday, December 4th, Srinivas Akkaraju acquired 513,872 shares of Versartis stock. The stock was bought at an average cost of $2.21 per share, for a total transaction of $1,135,657.12.

Shares of Versartis, Inc. (VSAR) opened at $2.25 on Friday. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.52 and a quick ratio of 1.52. Versartis, Inc. has a 52-week low of $1.60 and a 52-week high of $24.00.

Versartis (NASDAQ:VSAR) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported ($1.40) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.78). During the same period in the previous year, the company earned ($0.92) EPS. sell-side analysts expect that Versartis, Inc. will post -4.14 earnings per share for the current year.

Several research firms recently commented on VSAR. Canaccord Genuity reaffirmed a “buy” rating and issued a $9.00 price objective (down from $28.00) on shares of Versartis in a research report on Friday, September 22nd. Morgan Stanley reaffirmed an “equal weight” rating and issued a $4.00 price objective (up from $3.00) on shares of Versartis in a research report on Friday, September 22nd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $14.00 price objective (down from $34.00) on shares of Versartis in a research report on Friday, September 22nd. SunTrust Banks cut shares of Versartis from a “buy” rating to a “hold” rating and cut their price target for the stock from $25.00 to $4.00 in a research report on Friday, September 22nd. Finally, Cowen cut shares of Versartis from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $45.00 to $3.00 in a research report on Friday, September 22nd. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and three have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $7.22.

Several institutional investors have recently added to or reduced their stakes in the company. Parametric Portfolio Associates LLC increased its stake in shares of Versartis by 1.7% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 32,597 shares of the biopharmaceutical company’s stock worth $569,000 after purchasing an additional 535 shares during the last quarter. Schwab Charles Investment Management Inc. increased its stake in shares of Versartis by 0.6% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 109,409 shares of the biopharmaceutical company’s stock worth $1,910,000 after purchasing an additional 627 shares during the last quarter. The Manufacturers Life Insurance Company increased its stake in shares of Versartis by 4.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 26,326 shares of the biopharmaceutical company’s stock worth $459,000 after purchasing an additional 1,204 shares during the last quarter. Rhumbline Advisers increased its stake in shares of Versartis by 4.2% during the 2nd quarter. Rhumbline Advisers now owns 35,388 shares of the biopharmaceutical company’s stock worth $618,000 after purchasing an additional 1,420 shares during the last quarter. Finally, Alps Advisors Inc. increased its stake in shares of Versartis by 6.2% during the 2nd quarter. Alps Advisors Inc. now owns 31,780 shares of the biopharmaceutical company’s stock worth $555,000 after purchasing an additional 1,845 shares during the last quarter. Institutional investors own 49.18% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.chaffeybreeze.com/2017/12/08/versartis-inc-vsar-director-purchases-893961-00-in-stock.html.

Versartis Company Profile

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.

Insider Buying and Selling by Quarter for Versartis (NASDAQ:VSAR)

Receive News & Ratings for Versartis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply